

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. P1101P1	RECEIVED JAN 27 1998	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI		Examiner: C. Kaufman
	Filing Date: February 9, 1998	09 JAN 27 1998	Group Art Unit: 4647 1646

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CUN ↓		2002/0098550 A1 (serial no. 10/005,842)	07/25/2002	Jian Ni et al.			
		2002/0072091 A1 (serial no. 09/874,138)	06/13/2002	Jian Ni et al.			
		09/565,009	05/04/2000	Jian Ni et al.			
		60/148,939	08/13/1999	Jian Ni et al.			
		60/133,238	05/07/1999	Jian Ni et al.			
		60/132,498	05/04/1999	Jian Ni et al.			
		09/042,583	03/17/1998	Jian Ni et al.			
		60/054,021	07/29/1997	Jian Ni et al.			
CUN		60/040,846	03/17/1997	Jian Ni et al.			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

CUN ↓ CUN		Brojatsch, J. et al. "CAR1, a TNFR-Related Protein, Is a Cellular Receptor for Cytopathic Avian Leukosis-Sarcoma Viruses and Mediates Apoptosis." Cell, Vol. 87 (1996). pp. 845-855.
		Chapman, Barbara. "A region of the 75 kDa neurotrophin receptor homologous to the death domains of TNFR-I and Fas." B.S. Chapman/FEBS Letters, Vol. 374 (1995). pp. 216-220.
		Pan, G. et al. "An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for TRAIL." Science, Vol. 277 (1997). pp. 815-818
		Rabidezeh, S. et al. "Induction of Apoptosis by the Low-Affinity NGF Receptor." Science, Vol. 261 (1993). pp. 345-348.
		Tartaglia, L. et al. "A Novel Domain within the 55kd TNF Receptor Signals Cell Death." Cell, Vol. 74 (1993). pp. 845-853.

EXAMINER <i>Chen M. Kuf</i>	DATE CONSIDERED <i>10/28/03</i>
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 1

INFORMATION DISCLOSURE STATEMENT	Docket No. P1101P1	RECEIVED 1501 0000 1000/2000	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI		Examiner: C. Kaufman
	Filing Date: February 9, 1998	03 JAN 22 PM 12:23	Group Art Unit: T637/646

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CM		6,313,269	11/06/2001	Keith C. Deen et al.			
		08/916,625	08/22/1997	Keith C. Deen et al.			
		08/853,684	05/09/1997	Keith C. Deen et al.			
CM		60/041,230	03/14/1997	Keith C. Deen et al.			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
CM		WO 0077191	12/21/2000	<del>WIPO</del> PCT				

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

--	--

EXAMINER	Clan M. Kaufman	DATE CONSIDERED	10/28/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			
Form PTO-A820 (also form PTO-1449)		SHEET 1 OF 1	

<b>INFORMATION DISCLOSURE STATEMENT</b>	Docket No. P1101PI	Application No. 09/020,746
	Applicant(s): Avi J. ASHKENAZI	Examiner: C. Kaufman
	Filing Date: February 9, 1998	Group Art Unit: 1647 1646

### U.S. PATENT DOCUMENTS

Examiner Initial	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (IF APPROPRIATE)
CM		2002/0160446 A1 (serial no. 09/811,088)	10/31/2002	Douglas A. Holtzman			
		2002/0048785 A1 (serial no. 09/757,421)	04/25/2002	Douglas A. Holtzman			
		09/712,726	11/14/2000	David Gearing			
		08/843,652	04/16/1997	Douglas A. Holtzman			
		08/843,651	04/16/1997	Douglas A. Holtzman			
ur		08/820,364	03/12/1997	David Gearing			

### FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

--

EXAMINER <i>Clara M. King</i>	DATE CONSIDERED 10/28/03
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO-A820 (also form PTO-1449)	SHEET 1 OF 1

FORM PTO-1449

U.S. Dept. of Commerce  
Patent and Trademark Office

Atty Docket No.

F1101P1

Serial No.

09/020,746

## LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Ashkenazi et al.

Filing Date

09 Feb 1998

Group

1647 1646

## U.S. PATENT DOCUMENTS

aminer tials		Document Number	Date	Name	Class	Subclass	Filing Date
cur	1	4,855,235	08.08.89	Takahashi et al.			
	2	5,153,118	06.10.92	Wright, Jr. et al.			
	3	5,158,885	27.10.92	Bradstock et al.			
cur	4	6,417,328	09.07.02	Alnemri			

## FOREIGN PATENT DOCUMENTS

aminer tials		Document Number	Date	Country	Class	Subclass	Translation Yes No
Cur	5	WO 02/053727	11.07.02	PCT			
	6	WO 92/01047	23.01.92	PCT			
	7	WO 92/20791	26.11.92	PCT			
	8	WO 93/00109	07.01.93	PCT			
	9	WO 93/06213	01.04.93	PCT			
	10	WO 93/11236	10.06.93	PCT			
	11	WO 93/19172	30.09.93	PCT			
	12	WO 95/01438	12.01.95	PCT			
Cur	13	WO 95/15388	08.06.95	PCT			

## OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

Cur	14	Carter et al., "Antibody Engineering Using Very Long Template-Assembled Oligonucleotides" <u>Methods: A Companion to Methods in Enzymology</u> 3(3):183-192 (Dec 1991)
	15	Chuntharapai and Kim, "Generation of Monoclonal Antibodies to Chemokine Receptors" <u>Methods in Enzymology</u> 288:15-27 (1997)
	16	Ellis, S., "Recognition of HLA-B27 and Related Antigen by a Monoclonal Antibody" <u>Human Immunology</u> 5:49-59 (1982)
	17	Emery et al., "Osteoprotegerin Is a Receptor for the Cytotoxic Ligand Trail" <u>Journal of Interferon and Cytokine Research</u> (Abstract No. 2.17 from the 7th Intl. Tumor Necrosis Factor Congress May 17-21) 18(5):A-47 (May 1998)
	18	Fishwild et al., "High-Avidity Human IgGk Monoclonal Antibodies From a Novel Strain of Minilocus Transgenic Mice" <u>Nature Biotechnology</u> , 14(7):845-851 (Jul 1996)
	19	Glassy, M., "Production methods for generating human monoclonal antibodies" <u>Human Antibodies &amp; Hybridomas</u> 4(4):154-165 (Oct 1993)
	20	<u>Handbook of Monoclonal Antibodies</u> , Ferrone et al. eds., Park Ridge, NJ:Noyes Publications, pps. 302-359 and Chapter 22 (1985)
	21	Hoogenboom, "Designing and optimizing library selection strategies for generating high-affinity antibodies" <u>Trends in Biotechnology</u> 15(2):62-70 (Feb 1997)
	22	Jones, Y., "Cytokine Receptor Complexes Versus Cell Adhesion Interactions - Upping the Affinity" (Abstract no. M11.OA.002 presented at the XVIIth IUCr Congress & General Assembly held in Glasgow, Scotland on August 4th-13th, 1999.) pps. 133
Cur	23	Kabat et al. <u>Sequences of Proteins of Immunological Interest</u> (NIH Publ. No. 91-3242), 5th edition

aminer

Claus M. Kay

Date Considered

10/28/03

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1101P1		Serial No. 09/020,746	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Ashkenazi et al.			
				Filing Date 09 Feb 1998		Group 2647 1646	
OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)							
CU	24	Lasky et al., "DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2" <u>DNA</u> 3(1):23-29 (1984)					
	25	Mendez et al., "Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice" <u>Nature Genetics</u> 15:146-156 (Feb 1997)					
	26	Neri et al., "Engineering recombinant antibodies for immunotherapy" <u>Cell Biophysics</u> 27(1):47-61 (Aug 1995)					
	27	Olsson and Kaplan, "Human-human hybridomas producing monoclonal antibodies of predefined antigenic specificity" <u>Proc. Natl. Acad. Sci. USA</u> 77(9):5429-5431 (1980)					
	28	Peterson, W., "Recombinant antibodies: alternative strategies for developing and manipulating murine-derived monoclonal antibodies" <u>Laboratory Animal Science</u> 46(1):8-14 (Feb. 1996)					
	29	Pluckthun., "Antibodies From Escherichia coli." <u>The Pharmacology Of Monoclonal Antibodies: Handbook of Experimental Pharmacology</u> , Rosenberg and Moore, eds., Berlin:Springer-Verlag, Chapter 11, Vol. 113:269-315 (1994)					
	30	Smith et al., "Cardiac Glycoside-Specific Antibodies in the Treatment of Digitalis Intoxication" <u>Antibodies in Human Diagnosis and Therapy</u> pps. 365-389 (1977)					
	31	Soderlind et al., "Phage display technology in antibody engineering: design of phagemid vectors and in vitro maturation systems" <u>Immunological Reviews</u> 130:109-124 (Dec 1992)					
	32	Steinitz et al., "EB virus-induced B lymphocyte cell lines producing specific antibody" <u>Nature</u> 269(5627):420-422 (Sep 29, 1977)					
	33	Vaughan et al., "Human Antibodies With Sub-nanomolar Affinities Isolated From a Large Non-immunized Phage Display Library" <u>Nature Biotechnology</u> 14:309-314 (1996)					
CU	34	Winter et al., "Making antibodies by phage display technology" <u>Annual Review of Immunology</u> 12:433-455 (1994)					
Examiner		Date Considered 10/28/03					
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							